Humana Inc. (NYSE:HUM) Shares Acquired by Cibc World Markets Corp

Cibc World Markets Corp boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 16.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,012 shares of the insurance provider's stock after buying an additional 2,660 shares during the quarter. Cibc World Markets Corp's holdings in Humana were worth $4,824,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Pzena Investment Management LLC increased its stake in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares during the period. FMR LLC grew its holdings in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider's stock worth $1,073,387,000 after acquiring an additional 643,291 shares in the last quarter. Retirement Systems of Alabama increased its position in shares of Humana by 735.9% in the 4th quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock valued at $55,563,000 after purchasing an additional 192,801 shares during the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Humana in the 3rd quarter valued at $50,102,000. Finally, Massachusetts Financial Services Co. MA lifted its position in shares of Humana by 42.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 391,657 shares of the insurance provider's stock worth $124,053,000 after purchasing an additional 115,820 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Remove Ads

Humana Stock Performance

Humana stock traded up $5.48 during mid-day trading on Monday, reaching $271.65. 1,252,835 shares of the company were exchanged, compared to its average volume of 1,714,263. The firm's 50-day simple moving average is $271.33 and its two-hundred day simple moving average is $276.25. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The firm has a market cap of $32.79 billion, a PE ratio of 27.30, a price-to-earnings-growth ratio of 2.05 and a beta of 0.57. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. Equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.30%. The ex-dividend date of this dividend is Friday, March 28th. Humana's payout ratio is 35.58%.

Insiders Place Their Bets

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.37% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HUM. Cantor Fitzgerald reissued a "neutral" rating and issued a $290.00 target price on shares of Humana in a report on Wednesday, February 12th. Piper Sandler increased their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. Truist Financial boosted their target price on Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. Royal Bank of Canada reiterated an "outperform" rating and issued a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Finally, Morgan Stanley reduced their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Eighteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.